Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DESOGESTREL ETHINYLESTRADIOL
PCO Manufacturing
DESOGESTREL ETHINYLESTRADIOL
150/20 Microgram
Unknown
Withdrawn
2009-12-31
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mercilon 150 micrograms/20 micrograms tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150 micrograms desogestrel and 20 micrograms ethinylestradiol. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Tablet. _Product imported from Greece._ White, round biconvex tablets, coded 'TR4' on one side and 'ORGANON' on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hormonal contraception. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Before starting Mercilon, a thorough general medical and gynaecological examination (including breasts and a cytological smear of the cervix) should be carried out and the family medical history carefully noted. Disturbances of the clotting mechanisms should be ruled out if any members of the family have suffered from thromboembolic diseases (e.g. deep vein thrombosis, stroke, myocardial infarction) at a young age. Pregnancy must be excluded ideally by a pregnancy test. As a precaution, thorough examinations should be conducted at approximately six month intervals during the use of the tablets. First cycle Tablet-taking from the first pack of Mercilon is started on the 1st day of the menstrual cycle, i.e. the first day of menstrual bleeding. One tablet is to be taken at around the same time of day on each of 21 consecutive days followed by a tablet-free interval of 7 days during which a withdrawal bleeding occurs. Subsequent cycles Tablet taking from the next pack of Mercilon is continued after the 7-day interval, beginning on the same day of the week as the first pack. Changing from another oral contraceptive The first tablet of Mercilon should be taken on the first day of bleeding that occurs after the intake of the last active tablet of Read the complete document